** Shares of rare neurological disease-focused pharma company Harmony Biosciences rise HRMY.O 3.5% to $31 premarket
** HRMY posts Q1 adj. profit of 78 cents per share, above analysts' estimate of 58 cents per share - data compiled by LSEG
** Company posts Q1 product revenue of $184.73 million, beating analysts' estimate of $182.9 million
** Company maintains its 2025 product revenue of $820 million to $860 million compared with estimates of $839.89 million
** As of last close, HRMY has fallen 12.9% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。